{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "SARS-CoV-2",
      "genetics",
      "immune response",
      "pandemic",
      "personalized medicine",
      "vaccines"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34303332",
  "DateCompleted": {
    "Year": "2022",
    "Month": "05",
    "Day": "10"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "06",
    "Day": "06"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.2174/1871526521666210720124950"
    ],
    "Journal": {
      "ISSN": "2212-3989",
      "JournalIssue": {
        "Volume": "22",
        "Issue": "1",
        "PubDate": {
          "Year": "2022"
        }
      },
      "Title": "Infectious disorders drug targets",
      "ISOAbbreviation": "Infect Disord Drug Targets"
    },
    "ArticleTitle": "Genetics and Vaccine Development for SARS-CoV2 in the Era of Personalized Medicine.",
    "Pagination": {
      "StartPage": "e200721194929",
      "MedlinePgn": "e200721194929"
    },
    "Abstract": {
      "AbstractText": [
        "Since the emergence of SARS-CoV-2 in late December 2019, scientists have been racing against time to effectively develop a vaccine. As the techniques of personalized medicine are becoming more understood and approachable for mankind, vaccinations using such technologies could advance the treatment of all patients taking into consideration their genetic and biochemical background. As such, we anticipate that patients will be treated more effectively and potentially have fewer symptoms and side effects. This perspective aims to raise awareness of the oncoming novel treatment of diseases, especially during the coronavirus pandemic."
      ],
      "CopyrightInformation": "Copyright\u00a9 Bentham Science Publishers; For any queries, please email at epub@benthamscience.net."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Biomedical and Biomolecular Sciences, Newcastle University, Newcastle, NE1 7RU, United Kingdom."
          }
        ],
        "LastName": "Tafanidou",
        "ForeName": "Eirini Konstantina",
        "Initials": "EK"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Pediatrics, University of Patras Medical School, 26504, Rio, Patras, Greece."
          }
        ],
        "LastName": "Gkentzi",
        "ForeName": "Despoina",
        "Initials": "D"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United Arab Emirates",
    "MedlineTA": "Infect Disord Drug Targets",
    "NlmUniqueID": "101269158",
    "ISSNLinking": "1871-5265"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "RNA, Viral"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "prevention & control"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Precision Medicine"
    },
    {
      "QualifierName": [],
      "DescriptorName": "RNA, Viral"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Vaccine Development"
    }
  ]
}